UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2020

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______________

Commission File Number: 1-9927

ADVANZEON SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware		95-2594724
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

2901 W. Busch Blvd. Suite 701 Tampa, FL		33618
(Address of principal executive offices)		(Zip Code)

 

813-517-8484

(Registrant’s telephone number, including area code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such fling requirements for the past 90 days. Yes☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 10, 2020, the Registrant had outstanding 117,516,838 shares of its $0.01 par value Common Stock.

 

ADVANZEON SOLUTIONS, INC.

 

 

TABLE OF CONTENTS

		Pages
PART I.	Financial Information
Item 1.	Consolidated Financial Statements
	Consolidated Balance Sheets as of June 30, 2020 (unaudited) and December 31, 2019	3
	Consolidated Statements of Operations for the Three and Six-Month Periods Ended June 30, 2020 and 2019 (unaudited)	4
	Consolidated Statement of Stockholders' Deficiency For the Three and Six-Month Periods Ended June 30, 2020 and 2019 (unaudited)	5
	Consolidated Statements of Cash Flows for the Six-Month Periods Ended June 30, 2020 and 2019 (unaudited)	6
	Notes to Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosure about Market Risk	23
Item 4.	Controls and Procedures	23
PART II.	Other Information
Item 1.	Legal Proceedings	25
Item 1A.	Risk Factors	25
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25
Item 3.	Exhibits	30

 

 

PART I – FINANCIAL INFORMATION

ITEM 1. Consolidated Financial Statements

ADVANZEON SOLUTIONS, INC.

 

CONSOLIDATED BALANCE SHEETS

June 30, 2020 (unaudited) and December 31, 2019

 

		June 30, 2020				December 31,
		(unaudited)				2019
ASSETS
CURRENT ASSETS
Cash		$	145,915			$	69,327
Restricted cash			845,340				—
Accounts receivable			40,990				29,769
Current portion of right of use asset			136,230				113,911
Other current assets			657,025				826,597
Total current assets			1,825,500				1,039,604
PROPERTY, PLANT, AND EQUIPMENT
Property and equipment, net			5,683				1,239
Leasehold improvements, net			—				—
Total property, plant, and equipment			5,683				1,239
RIGHT OF USE ASSET, NET OF CURRENT PORTION			179,221				146,880
TOTAL ASSETS		$	2,010,404			$	1,187,723
CURRENT LIABILITIES
Related party loans payable		$	102,229			$	342,670
Account payable			403,265				99,441
Debt			10,416,176				12,352,189
Contingent liability			642,659				642,659
Current portion of lease liability			136,230				113,911
Other accrued expenses			13,742,192				15,891,787
Total current liabilities			25,442,751				29,442,657
LEASE LIABILITY, NET OF CURRENT PORTION			179,221				146,880
TOTAL LIABILITIES			25,621,972				29,589,537
STOCKHOLDERS' DEFICIENCY
Preferred stock, $.001 par value; 1,000,000 shares authorized as of June 30, 2020 and December 31, 2019			—				—
Series C Convertible Preferred; $.001 par value; 14,400 shares authorized; 10,434 shares issued and outstanding as of June 30, 2020 and December 31, 2019			10				10
Series D Convertible Preferred; $.001 par value; 7,000 shares authorized; 250 shares issued and outstanding as of June 30, 2020 and December 31, 2019			—				—
Remaining Preferred stock; $.001 par value; 978,600 shares authorized as of June 30, 2020 and December 31, 2019			—				—
Common stock, $0.01 par value; 1,000,000,000 shares authorized; 13,201,582 shares reserved; 116,751,439 and 71,661,656 shares issued  and outstanding as of  June 30, 2020 and December 31, 2019, respectively			1,167,514				716,617
Additional paid in capital			35,361,980				28,719,246
Accumulated deficit			(60,141,072	)			(57,837,687	)
Total stockholders' deficiency			(23,611,568	)			(28,401,814	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY		$	2,010,404			$	1,187,723

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

ADVANZEON SOLUTIONS, INC.

 

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three and Six-Month Periods Ended June 30, 2020 and 2019 (unaudited)

		Three-Month Period Ended								Six-Month Period Ended
		June 30,								June 30,
		2020				2019				2020				2019
Revenues:
Obstructive sleep apnea (OSA)		$	103,444			$	90,453			$	230,992				158,376
Total revenues			103,444				90,453				230,992				158,376
Costs and expenses:
Costs of revenues			65,000				66,157				129,909				107,817
General and administrative			715,397				416,039				1,311,462				841,843
Depreciation and amortization			312				235				623				440
Total costs and expenses			780,709				482,431				1,441,994				950,100
Loss from operations			(677,265	)			(391,978	)			(1,211,002	)			(791,724	)
Other income (expense):
Interest expense			(707,774	)			(341,178	)			(1,102,403	)			(669,193	)
Interest income			—				5,994				20				5,994
Legal settlement			—				112,172				—				112,172
Forgivable SBA EIBL loan advance			10,000				—				10,000				—
Total other expense			(697,774	)			(223,012	)			(1,092,383	)			(551,027	)
Net loss		$	(1,375,039	)		$	(614,990	)		$	(2,303,385	)		$	(1,342,751	)
PER SHARE INFORMATION
Net Loss Per Common Share		$	(0.01	)		$	(0.01	)		$	(0.02	)		$	(0.02	)
Weighted Average Number of Common
Shares Outstanding			79,534,495				67,361,656				75,598,076				67,027,954

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

ADVANZEON SOLUTIONS, INC.

 

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIENCY

		Series C convertible Preferred Stock Number of Shares				Series C Convertible Preferred Stock Amount				Common Stock Number of Shares				Common Stock Amount				Additional Paid - in Capital				Accumulated Deficit				Total
Balance at December 31, 2018			10,434			$	10				66,661,656			$	666,617			$	28,012,007			$	(54,581,873	)		$	(25,903,239	)
Stock Issued for Services			—				—				200,000				2,000				14,000				—				16,000
Sale of Stock			—				—				500,000				5,000				10,000				—				15,000
Net Loss			—				—				—				—				—				(727,761	)			(727,761	)
Balance at March 31, 2019			10,434				10				67,361,656				673,617				28,036,007				(55,309,634	)			(26,600,000	)
Stock Issued for Services			—				—				—				—				—				—				—
Sale of Stock			—				—				—				—				—				—				—
Net Loss			—				—				—				—				—				(614,990	)			(614,990	)
Balance at June 30, 2019			10,434				10				67,361,656				673,617				28,036,007				(55,924,624	)			(27,214,990	)
Stock Issued for Services			—				—				—				—				—				—				—
Sale of Stock			—				—				—				—				—				—				—
Net Loss			—				—				—				—				—				(747,801	)			(747,801	)
Balance at September 30, 2019			10,434				10				67,361,656				673,617				28,036,007				(56,672,425	)			(27,962,791	)
Stock Issued for Services			—				—				4,300,000				43,000				430,000				—				473,000
Sale of Warrants			—				—				—				—				253,239				—				253,239
Sale of Stock			—				—				—				—				—				—				—
Net Loss			—				—				—				—				—				(1,165,262	)			(1,165,262	)
Balance at December 31, 2019			10,434				10				71,661,656				716,617				28,719,246				(57,837,687	)			(28,401,814	)
Stock Issued for Services			—				—				—				—				—				—				—
Sale of Warrants			—				—				—				—				—				—				—
Sale of Stock			—				—				—				—				—				—				—
Net Loss			—				—				—				—				—				(928,346	)			(928,346	)
Balance at March 31, 2020			10,434				10				71,661,656				716,617				28,719,246				(58,766,033	)			(29,330,160	)
Stock Issued for Services			—				—				—				—				—				—				—
Sale of Warrants			—				—				—				—				18,251				—				18,251
Sale of Stock			—				—				45,089,783				450,897				6,624,483				—				7,075,380
Net Loss			—				—				—								—				(1,375,039	)			(1,375,039	)
Balance at June 30, 2020			10,434				10				116,751,439				1,167,514				35,361,980				(60,141,072	)			(23,611,568	)

 

  

The accompanying notes are an integral part of these consolidated financial statements.

 

ADVANZEON SOLUTIONS, INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Six-Month Periods Ended June 30, 2020 and 2019 (unaudited)

 

		Six-Month Periods Ended
		June 30,
		2020				2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		$	(2,303,385	)		$	(1,342,751	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			623				440
Stock issued for services			—				16,000
Amortization of right of use assets			54,660				25,579
Net changes in assets and liabilities:
Accounts receivable			(11,221	)			(2,756	)
Other current assets			169,572				(712,065	)
Payments on lease liabilities			(54,660	)			(25,579	)
Accounts payable			51,383				210,951
Other accrued expenses			1,215,572				742,356
Net cash used in operating activities			(877,456	)			(1,087,825	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant, and equipment			(5,067	)			(1,549	)
Net cash used in investing activities			(5,067	)			(1,549	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from promissory notes			559,360				1,070,250
Proceeds from PPP loan			1,243,840				—
Payments on debt			(17,000	)			—
Sale of stock			18,251				15,000
Net cash provided by financing activities			1,804,451				1,085,250
Net increase (decrease) in cash			921,928				(4,124	)
CASH - Beginning of Year			69,327				25,036
CASH AND RESTRICTED CASH - END OF PERIOD		$	991,255			$	20,912
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest		$	—			$	—
Income taxes		$	—			$	—
Recording of right of use assets under
lease agreements (ASU 2016-02)		$	135,075			$	119,640
Schedule of non-cash investing transactions:
Convertible promissory note and accrued interest
converted to common stock		$	7,075,380			$	—

 

The accompanying notes are an integral part of these consolidated financial statements.

 

ADVANZEON SOLUTIONS, INC.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

1.

DESCRIPTION OF THE COMPANY’S BUSINESS AND BASIS OF PRESENTATION

The consolidated financial statements include the accounts of Advanzeon Solutions, Inc and its wholly owned subsidiary, and its respective subsidiaries (collectively referred to herein as, the “Company” ,“Advanzeon” ,“we”, “us” or “our”).

In the opinion of management, the accompanying unaudited financial statements contain all adjustments necessary to present fairly the Company's financial position as of December 31, 2019, the changes therein for the three and six-month periods then ended and the results of operations for the three and six-month periods ended June 30, 2020 and 2019.

The financial statements included in the Form 10-Q are presented in accordance with the requirements of the Form and do not include all of the disclosures required by accounting principles general accepted in the United States of America. For additional information, reference is made to the Company's annual report on Form 10-K for the fiscal year ended December 31, 2019, filed April 9, 2020. The results of operations for the three and six-month periods ended June 30, 2020 and 2019 are not necessarily indicative of operating results for the full year.

2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Established in 1969, Advanzeon Solutions, Inc., (formerly Comprehensive Care Corp.) (“Advanzeon”, “we”, “Parent”, or the “Company”), through its wholly-owned subsidiary Pharmacy Value Management Solutions, Inc., and its wholly-owned subsidiaries during 2015, and partly in 2016, provided managed care services by acting as the administrator for certain administrative service agreements in the behavioral health and substance abuse fields. We primarily offered these services to commercial, Medicare, Medicaid, Children’s Health Insurance Program (“CHIP”) health plans, as well as self-insured companies. Our managed care operations consisted solely of servicing administrative service agreements. Starting in July of 2015, we implemented our comprehensive sleep apnea program, called “SleepMaster Solutions” ™. SleepMaster Solutions (“SMS”) utilizes an administrative system for the convenient identification/testing and therapy of Obstructive Sleep Apnea (“OSA”). We partnered with a national health care provider by initiating a sleep apnea wellness program whereby we screened, tested and when needed, offered treatment programs for treating this disorder. We also contracted with a union to treat its driver members. Beginning in 2017, our only business was our SMS sleep apnea program.

The Company has elected to not adopt the option available under United States generally accepted accounting principles (“GAAP”) to measure any eligible financial instruments or other items at fair market value at this time. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting, except as otherwise required by GAAP.

Inter-company accounts and transactions have been eliminated in consolidation. Certain minor reclassifications of prior period amounts have been made to conform to the current period presentation.

Use of Estimates - The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts. Actual results could differ from these estimates. Estimates involved in the determination of an allowance for doubtful accounts receivable are considered by management as particularly susceptible to material change in the next year. Other significant estimates relate to stock-based compensation, warrants and beneficial conversion features.

Accounts Receivable - Accounts receivable is carried at its estimated collectible value. Since customer credit is generally extended on a short-term basis, accounts receivable does not bear interest and are uncollateralized. We manage credit risk and determine necessary allowances by evaluating customers’ credit worthiness before extending credit and periodically for collectability, based primarily on customers’ past credit history and current financial conditions and general economic conditions, results of prior collection efforts, the relative strength of our relationship therewith and, in the event of a dispute, its legal position and the estimated cost of proposed collection proceedings. Management has not established a policy for when to charge off uncollectible accounts receivable or to use external collection agencies and makes such decisions on a case-by-case basis. The maximum losses that the Company would incur if a customer failed to pay would be limited to the carrying value of the receivable. 

 

Revenue Recognition - In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, "Revenue from Contracts with Customers", the Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Generally, this occurs upon shipment of the CPAP to their customer or when the test is performed.

Property and Equipment - Property and equipment (Note 4) is stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives ranging from 2 to 12 years.

Leasehold Improvement - Leasehold improvement (Note 5) is stated at cost less accumulated amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives ranging from 2 to 12 years. Leasehold improvements are amortized over the shorter of the lease term or the asset’s useful life.

Fair Value Measurements - The carrying amounts of cash, accounts receivable and accounts payable approximate their estimated fair value due to the short-term nature of these instruments. Since our other financial liabilities are not traded in an open market, we generally use a present value technique, which is a level 3 input, as defined in GAAP, to measure the estimated fair value of these financial instruments, except for valuing stock options and warrants (see below). The rate used for discounting expected cash flows is a risk-free rate adjusted for systematic and unsystematic risk.

The carrying amounts of long-term debt and estimated fair values of the attached warrants at June 30, 2020 and December 31, 2019 are as follows:

		June 30, 2020								December 31, 2019
						Estimated								Estimated
						Fair Value of								Fair Value of
		Carrying				Attached				Carrying				Attached
		Amount				Warrants				Amount				Warrants
Convertible promissory notes		$	5,956,533			$	—			$	7,564,173			$	—
Short term notes payable			3,215,803				—				4,788,016				—
Loan payable related party			102,229				—				342,670				—
PPP Loan			1,243,840				—				—				—
		$	10,518,405			$	—			$	12,694,859			$	—

 

During the six-month period ended June 30, 2020, there have been 10 additional convertible notes issued totaling $547,360. During the six-month period ended June 30, 2020, 53 convertible notes totaling $3,727,213 plus accrued interest was converted to stock.

Cost of Revenues - Costs of services consist of supplies and operating expenses. Supplies are recognized in the period in which a patient receives the supplies.

Right of Use Assets and Lease Liabilities - During the quarter ended March 31, 2019, the Company implemented Accounting Standards Update 2016-02, Leases. Under the new guidance, a lessee must record a liability for lease payments (referred to as the lease liability) and an asset for the right to use the leased asset during the lease term (referred to at the right of use asset) for all leases, regardless of whether they are designated as finance or operating leases. This election requires the lessee to recognize lease expense on a straight-line basis over the lease term. The right of use assets and corresponding right of use liabilities have been recorded using the present value of the leases. See Notes 10 and 11 within the financial statement for additional disclosure on leases.

Income Taxes - We are subject to the income tax jurisdictions of the U.S. and multiple state tax jurisdictions. However, our provisions for income taxes for 2020 and 2019 include only state income taxes. 

 

Management has evaluated our tax positions taken or to be taken on income tax returns that remain subject to examination (i.e., tax years 2017 and thereafter federally), and has concluded that there have been no uncertain tax positions (as defined in GAAP) taken that require recognition or disclosure in the consolidated financial statements. In the event of any income tax-related interest or penalties are incurred, they would be included in general and administrative expense.

Concentration of Credit Risk - The Company maintains its cash and cash equivalents with a financial institution which management believes to be of high credit quality. Their accounts are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 in coverage. The Company had an uninsured cash balance of $595,340 as of June 30, 2020 and no uninsured cash balances as of December 31, 2019.

Stock Options and Warrants - We grant stock options and warrants to our employees, non-employee directors, note holders and certain consultants allowing them to purchase our common stock pursuant to approved terms. The estimated value of the warrants issued with debt instruments is recorded as a discount on notes payable and amortized as interest expense over the term of the notes using the effective interest method.

3.

CURRENT ASSETS

Cash and Restricted Cash - On April 23, 2020, the Company’s wholly owned subsidiary, Pharmacy Value Management Solutions, Inc. (‘PVMS”) received a loan in the principal amount of $1,243,840 from Mechanics Bank (the “Bank”) pursuant to the Paycheck Protection Program “PPP”. On May 22, 2020, the Bank notified PVMS that the loan was in default as a result of false statements made in the loan application. PVMS disputes the Bank’s claim and believes that it made no false statements in it's PPP loan application. The statements relate to the number of employees and the monthly payroll amounts. As a result, PVMS’ account with Mechanics Bank has been frozen with a balance of $845,340. Both PVMS and the Bank are seeking guidance from the Small Business Administration as to how to resolve this dispute. Until resolved, it is likely that this account will remain frozen.

 

Cash and restricted cash consists of the following at June 30, 2020 and December 31, 2019:

 

		June 30, 2020				December 31, 2019
Cash		$	145,915			$	69,327
Restricted Cash			845,340				—
Total cash and restricted cash shown in the
consolidated statement of cash flows		$	991,255			$	69,327

 

Other current assets consists of the following at June 30, 2020 and December 31, 2019:

		June 30, 2020				December 31, 2019
Loans to others		$	34,406			$	42,676
Security and lease deposits			3,500				3,500
Capitalized portion of lease			1,237				1,808
Prepaid expenses			288,487				452,953
Miscellaneous receivable			329,395				325,660
Other current asset		$	657,025			$	826,597

 

 

4.

PROPERTY AND EQUIPMENT

 

Property and equipment, net, consists of the following at June 30, 2020 and December 31, 2019:

		June 30, 2020				December 31, 2019
Property and equipment		$	6,616			$	1,549
Less accumulated depreciation			(933	)			(310	)
Property and equipment - net		$	5,683			$	1,239

Depreciation expense for the six-month periods ended June 30, 2020 and 2019 is $623 and $141, respectively. A laptop was acquired in January of 2020.

5.

LEASEHOLD IMPROVEMENT

 

Leasehold improvement, net, consists of the following at June 30, 2020 and December 31, 2019:

		June 30, 2020				December 31, 2019
Leasehold improvements		$	2,992			$	2,992
Less accumulated amortization			(2,992	)			(2,992	)
Leasehold improvements - net		$	—			$	—

 

Amortization expense for the six-month periods ended June 30, 2020 and 2019 is $0 and $299, respectively.

6.

RELATED PARTY LOANS PAYABLE

 

The Company has received financing from Management of the Company as well as from members of our Board of Directors. These individuals are deemed to be related parties to the Company and their indebtedness must be disclosed separately.

As of June 30, 2020 and December 31, 2019, there are the following related party notes payable:

		June 30, 2020				December 31, 2019
Related party loans payable		$	102,229			$	342,670

 

7.

DEBT

 

As of June 30, 2020 and December 31, 2019, the balance was as follows:

		June 30, 2020				December 31, 2019
Notes payable		$	10,416,176			$	12,352,189

 

During the six-month period ended June 30, 2020, there have been 10 additional convertible-promissory notes totaling $547,360. There have been 53 convertible-promissory notes totaling $3,727,213 converted to 39,652,283 shares of common stock. 

 

On April 23, 2020, the Company’s wholly owned subsidiary, Pharmacy Value Management Solutions, Inc. (‘PVMS”) received a loan in the principal amount of $1,243,840 from Mechanics Bank (the “Bank”) pursuant to the PPP. On May 22, 2020, the Bank notified PVMS that the loan was in default as a result of false statements made in the loan application. PVMS disputes the Bank’s claim and believes that it made no false statements in its PPP loan application. The statements relate to the number of employees and the monthly payroll amounts. As a result, PVMS’ account with Mechanics Bank has been frozen with a balance of $845,340. Both PVMS and the Bank are seeking guidance from the Small Business Administration as to how to resolve this dispute. Until resolved, it is likely that this account will remain frozen.

Break-out of debt between the parent company and our subsidiary PVMS is as follows:

		June 30, 2020				December 31, 2019
Advanzeon parent		$	3,381,163			$	5,010,016
PVMS			7,035,013				7,342,173
		$	10,416,176			$	12,352,189

At Advanzeon, the total notes issued year-to-date and their dollar values were as follows:

		June 30, 2020				December 31, 2019
Number of notes issued			2				—
Dollar value		$	165,360			$	—

All debts issued during the six-month period ended June 30, 2020 are short-term in nature and have a stated interest rate of 10%.

At PVMS, the total of notes issued year-to-date and their dollar values were as follows:

		June 30, 2020				December 31, 2019
Number of notes issued			8				51
Dollar value		$	382,000			$	2,289,250

All debt is short-term in nature, one-year maturity date. All debt issued has a stated interest rate of 12%.

 

8.

CONTINGENT LIABILITY

Contingent liability consisted of 3 items:

1.

A lawsuit against the Company for $450,000 from the son of a deceased promissory note holder. This matter has been dismissed twice by the judge but is ongoing due to appeals. The case has been dormant over a year. The Court has not dismissed it for lack of prosecution yet. The Court does this on its own motion and because of COVID, it is not doing this at this time.

2.

Interest payable in the amount of $171,247 to the same person listed in (1). This interest is related to the lawsuit referenced in (1).

3.

Advanzeon won a decision on a court case against Universal Healthcare. The attorney's fees relating to this matter total $21,412. This fee will be paid out of the proceeds of the case when collected.

 

 

 

As of June 30, 2020 and December 31, 2019, the balance of this indebtedness is as follows:

 

		June 30, 2020				December 31, 2019
Disputed note payable		$	450,000			$	450,000
Disputed interest payable			171,247				171,247
Pending attorney fees			21,412				21,412
Total contingent liability		$	642,659			$	642,659

 

 

9.

OTHER ACCRUED LIABILITIES

As of June 30, 2020 and December 31, 2019, the balance of other accrued liabilities is as follows:

		June 30, 2020				December 31, 2019
Management compensation		$	8,907,258			$	8,873,802
Accrued interest non-related party			4,760,728				5,956,368
Board of Director fees			37,500				1,050,000
State fees			—				2,800
Payroll liabilities			14,047				—
Other accrued liabilities			22,659				8,817
Total other accrued debt		$	13,742,192			$	15,891,787

10.

RIGHT OF USE ASSETS

The Company entered into two leases, one for office space and one for an automobile lease that are classified as right of use assets and lease liabilities. The Company pays the lease payments on a residential unit in California that is used as an office/residential unit for certain of its marketing personnel. The lease is on a month-to month basis. The Company has occupied this unit for the past approximately 1-1/2 year period and intends to do so for the foreseeable future. The lease for the Company’s office space expire in June 2022.The lease for the automobile expires in June 2021.As the implicit interest rate is not readily identifiable in the leases, the Company calculated the present value of the leases using the average commercial real estate interest rate of 5.50% at the commencement of the office leases and the interest of 2.99% for the automobile lease. Applying the commercial rate, the Company calculated the present value of $339,833 for the office leases and $29,037 for the automobile leasing that are being amortized over the life of the leases. 

 

As of June 30, 2020, the right of use assets associated with future operating leases are as follows:

Total present value of right of use assets
under lease agreements		$	368,870
Amortization of right of use assets			(53,419	)
Total right of use assets as of June 30, 2020		$	315,451

 

Total amortization expense related to the right of use assets under the lease agreements was $54,660 and $25,579 for the six-month periods ended June 30, 2020 and 2019, respectively.

11.

RIGHT OF USE LEASE LIABILITIES

As disclosed in Note 10, the Company entered into two leases for office space prior to the quarter ended June 30, 2020 that are classified as right of use assets and lease liabilities.

As of June 30, 2020, the lease liabilities associated with future payments due under the leases are as follows:

Total present value of future lease payments		$	368,870
Principal payments made as of the six month period ended June 30, 2020			(53,419	)
Total right of use lease liabilities as of June 30, 2020		$	315,451

The following is a schedule of future minimum lease payments under the right of use lease agreements together with the present value of the net minimum lease payments as of June 30, 2020:

Total future minimum lease payments		$	336,671
Less present value discount			21,220
Total right of use lease liabilities as of June 30, 2020			315,451
Less current portion due within one year			136,230
Long-term right of use liabilities		$	179,221

 

 

Total maturities of lease liabilities as of June 30, 2020 are as follows:

				Total future
				minimum lease				Present value				Right of use
				payments				discount				lease liabilities
	2021			$	150,103			$	13,873			$	136,230
	2022				146,568				6,358				140,210
	2023				40,000				989				39,011
				$	336,671			$	21,220			$	315,451

12.

COMMON STOCK

During the six-month period ended June 30, 2020, the Company issued 45,089,783 shares of its common stock as follows:

 

On April 01, 2020, the Company issued 3,262,500 shares of its common stock to a board of director member who elected to convert director’s fees and salary totaling $652,500. The stock was issued at $0.20 per share.

On April 01, 2020, the Company issued 1,087,500 shares of its common stock to a board of director member who elected to convert director’s fees and salary totaling $217,500. The stock was issued at $0.20 per share.

On April 01, 2020, the Company issued 1,087,500 shares of its common stock to a board of director member who elected to convert director’s fees and salary totaling $217,500. The stock was issued at $0.20 per share.

On April 21, 2020, the Company issued 14,584,350 shares of its common stock to existing note holders who elected to convert promissory notes plus accrued and unpaid interest totaling $2,916,869. The stock was issued at $0.20 per share.

On April 21, 2020, the Company issued 1,327,252 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $265,450. The stock was issued at $0.20 per share.

On April 21, 2020, the Company issued 2,156,515 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $431,303. The stock was issued at $0.20 per share.

On May 15, 2020, the Company issued 1,263,745 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $139,012. The stock was issued at $0.11 per share.

On May 15, 2020, the Company issued 4,284,565 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $471,302. The stock was issued at $0.11 per share.

On May 15, 2020, the Company issued 7,210,168 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $793,118. The stock was issued at $0.11 per share.

On May 18, 2020, the Company issued 700,751 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $77,083. The stock was issued at $0.11 per share.

On May 21, 2020, the Company issued 502,434 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $55,268. The stock was issued at $0.11 per share. 

 

On May 25, 2020, the Company issued 319,627 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $35,159. The stock was issued at $0.11 per share.

On May 25, 2020, the Company issued 333,824 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $36,721. The stock was issued at $0.11 per share.

On May 26, 2020, the Company issued 781,206 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $85,933. The stock was issued at $0.11 per share.

On May 28, 2020, the Company issued 884,555 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $97,301. The stock was issued at $0.11 per share.

On May 29, 2020, the Company issued 937,116 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $103,083. The stock was issued at $0.11 per share.

On June 1, 2020, the Company issued 1,024,189 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $112,661. The stocks was issued at $0.11 per share.

On June 05, 2020, the Company issued 668,797 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $73,568. The stock was issued at $0.11 per share.

On June 05, 2020, the Company issued 603,987 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $66,439. The stock was issued at $0.11 per share.

On June 12, 2020, the Company issued 1,564,245 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $172,067. The stock was issued at $0.11 per share.

On June 18, 2020, the Company issued 504,957 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $55,545. The stock was issued at $0.11 per share.

During the six-month period ended June 30, 2019, the Company issued 700,000 shares of its common stock as follows:

On March 21, 2019, the Company issued 200,000 shares of its common stock to its Securities Exchange Commission counsel, who elected to take common stock in the Company as partial payment of its legal fees. The total value shares were valued at $0.08 per share on the total value of $16,000.

Additionally, on March 29, 2019, the Company issued 500,000 shares of its common stock to an existing shareholder and warrant holder, who elected to exercise his warrants to purchase 500,000 shares of the Company's common stock for $15,000. The warrants were issued during May of 2017 for $0.03 per share.

13.

LEGAL PROCEEDINGS

The Company previously reported that the litigation between Rotech Healthcare, Inc. and Pharmacy Value Management Solutions, Inc. settled. The Company rejected the draft settlement terms and continues to aggressively defend this litigation.

Except as disclosed above and in Item 1, all of the legal proceedings for the six-month period ended June 30, 2020, are disclosed in our annual report on Form10-K filed on April 9, 2020. 

 

14.

SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, the Company evaluated subsequent events through August 19, 2020, the date these financial statements were available to be issued. During its evaluation, the following subsequent events were identified:

Issuance of debt and warrants

Subsequent to the balance sheet date, the Company has issued $56,180 of convertible-promissory notes. All of the debt matures in 2021 and has a stated interest rate of 22% and is unsecured. Concurrent with the issuance of debt, the Company has issued 300,000 warrants at an average exercise price of $0.25. At the time of issuance, all warrants had a three or five year term.

Stock issued for conversion of debt and accrued interest

 The Company issued 765,399 shares of common stock for the conversion of debt and accrued interest. The total debt and accrued interest converted was $84,194 or $0.11 per share. 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

General

The following information should be read in conjunction with the financial statements and notes thereto and in conjunction with Managements’ Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.

This report includes forward-looking statements, the realization of which may be affected by certain important factors discussed previously above under Item 1A, “Risk Factors.”

Overview

The Company through its wholly owned subsidiary Pharmacy Value Management Solutions, Inc. administers and operates a medically driven sleep apnea program branded SleepMaster Solutions™ (“SMS”). Management believes that SMS is the largest provider of these combined services in the nation. We are in all 50 states and provide a turnkey solution designed to effectively keep drivers on the road with no down time, compliant with DOT regulations, improve their health, and significantly decrease legal liability risk for the employer. We are vertically integrated, and we provide a “Program” of services that addresses all the needs of a corporate transportation system, union or other driver-related organizations. We believe we are the only company capable of providing the full range of needed services in a timely manner.

Our services start with the identification of the target population and the potential risk the client currently has. We can do this through our SMS Program, which includes the ability to screen every driver to identify if signs and symptoms of sleep apnea are present. We can then take this data and provide the employer with a list of those drivers that should be tested and the statistical likelihood of the percentage of those drivers who will test positive for obstructive sleep apnea (OSA). Together with the employer/union, SMS provides a realistic time frame, actual total cost, and process for testing all drivers who need to be tested. For those drivers testing positive for OSA, we then provide the appropriate treatment such that the driver will meet the DOT requirements and remain on the road. We monitor 365 days per year driver’s usage of the treatment device according to DOT standards and we report that usage to all stakeholders as required/permitted. We utilize mathematical algorithms to determine if the driver is predicatively meeting the annual DOT requirements for usage. Using those predictive algorithms, we reach out to those drivers and provide case management, encouragement designed to solve problems such that the driver increases usage, if necessary, and remains compliant.

SMS constructed its model based upon the foregoing principles. The SMS Program includes all processes attended in sleep apnea screening, testing, treatment, monitoring and overall management of commercial drivers’ as well as their employers’ needs. We have successfully established relationships with national health care clinic providers, all with certified medical examiner (“CME”) status. These clinics total almost 1,000 throughout the U.S. We also have both formal and informal relationships with employers; municipalities; a significant veteran’s group; union and non-union driving organizations; suppliers of home sleep testing equipment and a variety of OSA treatment devices; and, a national network of telemedicine sleep specialists covering all 50 states. We have an internal medical team for governance and protocol purposes and a customer service department that interfaces directly with our drivers. We also have a marketing team that regularly interfaces with our existing accounts and markets our services to potential new accounts. Our services are performed utilizing a best medical practices model and an efficient, cost-effective delivery system. We obtain the required equipment on a per order basis from a durable medical equipment distributor.

Revenue is recognized when billed, which is approximately when the testing service is performed, or CPAP machine is shipped.

 

During the three-month period ending June 30, 2020, the majority of our revenue was received from patient referrals from only certain of the clinics operated by Concentra Health Services. During this period and as a result of the Coronavirus pandemic, the Department of Transportation (DOT), which had previously suspended the requirement that interstate commercial drivers have a prescribed DOT medical exam from a DOT certified medical examiner, extended the DOT medical exam suspension to expire September 30, 2020. This action by the DOT, coupled with the effect of the pandemic, caused a significant number of clinics that we rely upon for referrals to either continue to be closed, close anew or operate with reduced staffing and reduced capacity. All of the foregoing resulted in fewer patients. Additionally, many commercial drivers, who, but for the aforesaid medical exam suspension, would have gone to the Concentra clinics for their required DOT medical exam, elected to wait until the suspension expires. All of those events materially reduced our referral resources. We did continue to receive revenue from certain Concentra referrals, other clinic referrals and some of our in-house account, such as PG&E, the Veteran’s organization with whom we contract, and others, but this patient flow was materially reduced, as well. Our recently announced launch of our CoreChoice account (April 29, 2020), scheduled to launch this period, did not launch as a result of the pandemic. During this period, we successfully added new accounts which, principally due to the pandemic, have not yet launched. However, they are in the process of preparing to do so. As clinics reopen and staff returns, management expects to see revenue from these new accounts. We continue to experience the effect of these closures/reduced staffing and cannot predict when either our referral sources or our own operation will begin to normalize, resulting in more positive financial results. However, we continue to aggressively seek new accounts and work with our existing accounts to achieve increased patient flow.

Sources of Revenue

Three-month periods ended June 30, 2020 and 2019

A quantitative summary of our revenues by source category for the three-month periods ended June 30, 2020 and 2019:

			2020				2019				Change
OSA- related		$	103,444			$	90,453			$	12,991

Results of Operations

OSA services increased to $103,444 in 2020 from $90,453 in 2019. The increase was primarily the result of the Concentra account. Last year, on May 14, 2019, we reached an agreement with Concentra whereby Concentra engaged the Company, and the Company accepted the engagement, to serve as one of Concentra’s preferred national sleep apnea services provider. The launch was initiated during the fourth quarter of 2019.

While there was an increase in OSA services, the increase would have been greater without the clinics having to shut down due to the COVID-19 pandemic. As demonstrated in the first quarter of 2020, OSA services increased by $59,625 than in the comparable period of 2019. With the clinics having to be closed during the three months period ended June 30, 2020 due to the COVID-19 pandemic, there was only an increase of $12,990.

Cost of revenues decreased to $65,000 in 2020 from $66,157 in 2019. In 2019, the cost allocation was changed to reflect the cost and sales in the same month. This caused two months’ worth of charges in the month of April 2019. April 1, 2019 and April 30, 2019

General and administrative expense

General and administrative expense in total for the three month periods ended June 30, 2020 and 2019 was as follows:

	2020			$	715,397
	2019				416,039
	Change			$	299,358
	Percentage Change				71.95	%

 

We evaluate expenses at the Parent company level as well as at our PVMS subsidiary. Expenses at the Parent company level include overhead and the cost of being a public entity. Expenses at PVMS are solely related to the OSA services segment. A breakdown of these expenses for the three month periods ended June 30, 2020 and 2019 is as follows:

			2020				2019				Change				Percent Change
Parent			$	296,036			$	156,686			$	139,350				88.94	%
PVMS				419,361				259,353				160,008				61.70	%
Total			$	715,397			$	416,039			$	299,358				71.95	%

 

Parent Company Level

 

		2020				2019				Change				Percent Change
Professional fees		$	243,494			$	86,804			$	156,690				180.51	%
Travel expense			—				815				(815	)			-100.00	%
Board of Directors fees			57,500				37,500				20,000				53.33	%
Office supplies			417				287				130				45.30	%
Rent expense			(23,181	)			25,448				(48,629	)			-191.09	%
Other			17,806				5,832				11,974				205.33	%
Total G & A		$	296,036			$	156,686			$	139,350				88.94	%

Explanations of variations by line item follow:

Professional fees increased by $156,690. The increase is mainly due to new consulting service expenses in the total of $118,250 and an increase of $43,827 in legal fees in the three-month period ended June 30, 2020 compared to the three month period ended June 30, 2019.

Travel expense decreased by $815 due to due to the COVID-19 pandemic. Many clinics have been closed and those that are open have reduced staffs and we have been requested to not conduct any in person visits.

Board of Directors fees increased by $20,000 due to an additional $20,000 paid to a Board of director member.

Rent expense decreased by 48,629 due to office lease moving to subsidiary level as of January 01, 2020. The same will show as an increase on the subsidiary level.

Other general and administrative expense increased by $11,974. This increase was due to a new D&O Insurance expense of $14,205 while other miscellaneous items decreased by $1,421.

 

PVMS Subsidiary Level

		2020				2019				Change				Percent Change
Payroll related		$	243,871			$	110,167			$	133,704				121.36	%
Travel and related expense			9,059				51,897				(42,838	)			-82.54	%
Professional fees			57,265				39,250				18,015				45.90	%
Marketing costs			17,758				9,729				8,029				82.53	%
Dues and subscriptions			27				200				(173	)			-86.50	%
Office supplies			1,135				8,718				(7,583	)			-86.98	%
Rent expense			54,096				12,452				41,644				334.44	%
Other			36,150				26,940				9,210				34.19	%
Total G & A		$	419,361			$	259,353			$	160,008				61.70	%

Explanations of variations by line item follow:

Payroll related expenses increased $133,704. The company hired 4 employees in the three months ended June 30, 2020 that were not included in the comparable period in 2019. The Company paid our CEO $32,699 and accrued wages in the amount of $33,456 during the three months ended June 30, 2020.

Travel expense decreased by $42,838 due to due to the COVID-19 pandemic. Many clinics have been closed and those that are open have reduced staffs and we have been requested to not conduct any in person visits.

Professional Fees increased by $18,015. The increase is mainly due to an increase in accounting fees by $25,000 due to services for special projects. There was a decrease in legal fees by $13,485. The Company no longer used a law firm in the three months ended June 30, 2020 that were used in the comparable period in 2019.

Marketing costs increased by $8,029. The company hired an advertising firm in the 3rd quarter of 2019 to work on the company's website and other marketing responsibilities and is still with the company as of June 30, 2020.

Office supplies decreased by $7,583 due to office supplies were fully stocked going into the new year of 2020.

Rent expense increased by $41,644 due a decrease on to rent expense moving from parent level to subsidiary level as of January 01, 2020. The same will show as a decrease on the parent level.

Other general and administrative expense increased by $9,210. The increase is mainly due to a fraudulent charge of $9,500 and an increase in payroll taxes of $13,371 due to an increase in wages. There is a decrease in automobile expenses of $4,912 due to the COVID-19 pandemic.

Interest expense

Interest expense in total for the three-month periods ended June 30, 2020 and 2019 was as follows:

2020			$	707,774
2019				341,178
Change			$	366,596
Percentage Change				107.45	%

 

A breakdown of the interest expense for the three-month periods ended June 30, 2020 and 2019 is as follows:

			2020				2019				Change
Parent			$	492,340			$	163,093			$	329,247
PVMS				215,434				178,085				37,349
Total			$	707,774			$	341,178			$	366,596

Sources of Revenue

Six-month periods ended June 30, 2020 and 2019

A quantitative summary of our revenues by source category for the six-month periods ended June 30, 2020 and 2019:

			2020				2019				Change
OSA- related		$	230,992			$	158,376			$	72,616

 

Results of Operations

OSA services increased to $230,992 in 2020 from $158,376 in 2019. The increase was primarily the result of the Concentra account. Last year, on May 14, 2019, we reached an agreement with Concentra whereby Concentra engaged the Company, and the Company accepted the engagement, to serve as one of Concentra’s preferred national sleep apnea services provider. The launch was initiated during the fourth quarter of 2019.

While there was an increase in OSA services, the increase would have been greater without the clinics having to shut down due to the COVID-19 pandemic. As demonstrated in the first quarter of 2020, OSA services increased by $59,625 than in the comparable period of 2019. With the clinics having to be closed during the three months period ended June 30, 2020 due to the COVID-19 pandemic, there was only an additional increase of $12,990.

Cost of revenues increased to $129,909 in 2020 from $107,817 in 2019 due to an increase in sales.

General and administrative expense

General and administrative expense in total for the six-month periods ended June 30, 2020 and 2019 was as follows:

2020			$	1,311,462
2019				841,843
Change			$	469,619
Percentage Change				55.78	%

We evaluate expenses at the Parent company level as well as at our PVMS subsidiary. Expenses at the Parent company level include overhead and the cost of being a public entity. Expenses at PVMS are solely related to the OSA services segment. A breakdown of these expenses as June 30, 2020 and 2019 is as follows:

			2020				2019				Change				Percent Change
Parent			$	539,259			$	352,821			$	186,438				52.84	%
PVMS				772,203				489,022				283,181				57.91	%
Total			$	1,311,462			$	841,843			$	469,619				55.78	%

 

Parent Company Level

														Percent
		2020				2019				Change				Change
Professional fees		$	409,870			$	211,265			$	198,605				94.01	%
Travel expense			67				3,815				(3,748	)			-98.24	%
Board of Directors fees			95,000				75,000				20,000				26.67	%
Office supplies			495				351				144				41.03	%
Rent expense			—				51,277				(51,277	)			-100.00	%
Other			33,827				11,113				22,714				204.40	%
Total general and administrative		$	539,259			$	352,821			$	186,438				52.84	%

Explanations of variations by line item follow:

Professional fees increased $198,605. The increase is mainly due to new consulting service expenses in the total of $236,500 and an increase of $55,023 in legal fees in the six-month period ended June 30, 2020 compared to the six-month period ended June 30, 2019. Audit fees decreased by $66,300 and accounting fees decreased by $22,957 due to the fact that the 2015 - 2017 10-K was filed in January 2019.

Travel expense decreased $3,748 due to due to the COVID-19 pandemic. Many clinics have been closed and those that are open have reduced staffs and we have been requested to not conduct any in person visits.

Board of Directors fees increased $20,000 due to an additional $20,000 paid to a Board of director member.

Rent expense decreased $51,277 due to rent expense moving from parent level to subsidiary level as of January 01, 2020. The same will show as an increase on the subsidiary level.

Other general and administrative expense increased by $22,714. This increase was due to a new D&O Insurance expense of $26,174 while other miscellaneous items decreased $3,463.

 

PVMS Subsidiary Level

 

														Percent
		2020				2019				Change				Change
Payroll related		$	419,743			$	212,312			$	207,431				97.70	%
Travel and related expense			75,224				91,324				(16,100	)			-17.63	%
Professional fees			109,057				81,747				27,310				33.41	%
Marketing costs			34,592				17,229				17,363				100.78	%
Dues and subscriptions			208				640				(432	)			-67.50	%
Office supplies			4,077				17,577				(13,500	)			-76.80	%
Rent expense			65,933				23,001				42,932				186.65	%
Other			63,369				45,192				18,177				40.22	%
Total general and administrative		$	772,203			$	489,022			$	283,181				57.91	%

 

Explanations of variations by line item follow:

Payroll related expenses increased $207,431. The Company hired 4 employees during the six months ended June 30, 2020 that were not included in the comparable period in 2019. The Company paid our CEO $32,699 and accrued wages in the amount of $33,456 during the six months ended June 30, 2020.

Travel expense decreased $16,100 due to the COVID-19 pandemic. Many clinics have been closed and those that are open have reduced staffs and we have been requested to not conduct any in person visits.

Professional Fees increased $27,310. There is an increase in accounting fees by $25,000 due to services for special projects. Consulting fees increased $33,750 because the company hired 5 new consultants to bring in additional revenue. There was a decrease in legal fees by $23,657. The Company no longer used a law firm in the six months ended June 30, 2020 that was used in the comparable period in 2019.

Marketing costs increased by $17,363. The company hired an advertising firm in the 3rd quarter of 2019 to work on the company's website and other marketing responsibilities and is still with the company as of June 30, 2020.

Office supplies decreased by $13,500 due to office supplies were fully stocked going into the new year of 2020.

Rent expense increased $42,932 due to rent expense moving from parent level to subsidiary level as of January 01, 2020. The same will show as a decrease on the parent level.

Other general and administrative expense increased by $18,180 due to a fraudulent charge of $9,500 and an increase in payroll taxes of $10,764 because of an increase in wages. Other miscellaneous items increased by $6,876 due to revamp of website, employee benefits, and printing and postage for a conference. Automobile expenses decreased $3,078 due to the COVID-19 pandemic. Bad debt expense decreased $3,510 due to a decrease in bad debt in the six months ended June 30, 2020 than in the comparable period in 2019.

Interest expense

Interest expense in total for the six-month periods ended June 30, 2020 and 2019 was as follows:

2020			$	1,102,403
2019				669,193
Change			$	433,210
Percentage Change				64.74	%

 

A breakdown of the interest expense for the six-month periods ended June 30, 2020 and 2019 is as follows:

			2020				2019				Change
Parent			$	636,453			$	326,185			$	310,268
PVMS				465,950				343,008				122,942
Total			$	1,102,403			$	669,193			$	433,210

  

Financial Condition

Liquidity and Capital Resources

During the six-month period ended June 30, 2020, we funded our operations from revenues and $547,360 in private borrowings. As a result of the coronavirus pandemic some of our traditional sources of private borrowing have not been accessible. We have had to obtain private borrowing on terms less favorable than we were able to prior to the pandemic. We will continue to fund our operations from these sources until we are able to produce operating revenue sufficient to cover our cost structure. In the event we are not able to secure such funding, our operations will be adversely affected.

Short Term: We funded our operations with revenues from sales and private borrowings.

On April 23, 2020, the Company’s wholly owned subsidiary, Pharmacy Value Management Solutions, Inc. (‘PVMS”) received a loan in the principal amount of $1,243,840 from Mechanics Bank (the “Bank”) pursuant to the Paycheck Protection Program. On May 22, 2020, the Bank notified PVMS that the loan was in default as a result of false statements made in the loan application. PVMS disputes the Bank’s claim and believes that it made no false statements in its PPP loan application. The statements relate to the number of employees and the monthly payroll amounts. As a result, PVMS’ account with Mechanics Bank has been frozen with a balance of $845,340. Both PVMS and the Bank are seeking guidance from the Small Business Administration as to how to resolve this dispute. Until resolved, it is likely that this account will remain frozen.

 

During the period we continued toward our goal to be able to uplist our Common Stock to another trading platform. Among the actions is our attempt to reduce our stockholder’s deficiency by, among, other things, being able to convert a large portion of our corporate debt to equity. For the six months ended June 30, 2020, $3,727,213 of debt plus accrued interest was converted into 39,652,283 shares of Common Stock. All of the holders of the converted debt agreed, subject to several different conditions, to a one year lock-up from publicly offering the shares. The primary condition being to not publicly sell the shares until the earlier of (i) one year from the date of the exchange, or (ii) until the shares are tradable on the NASDAQ or comparable national exchange. The other condition for a block of 14,584,350 shares received in an exchange has the lock-up as the earlier of one year or such time as our Common Stock has an average trading volume of no less than 500,000 shares for 30 consecutive trading days.

Subsequent Events

Subsequent to June 30, 2020, we issued a convertible promissory note in the principal amount of $56,180. The term of the note is 12 months and the interest rate is 10% per annum.

In August we announced that we will start using a disposable home sleep test device known as the WatchPAT™ ONE which utilizes cloud-based technology for the immediate upload of testing data. This feature will streamline the Company's receipt of test data and its ability to render faster obstructive sleep apnea (“OSA”) test results - critical, in light of the increased OSA testing reasonably to be anticipated when DOT-required medical exams resume. With the WatchPAT™ ONE, we can measure the patient's PAT® signal, heart rate, oximetry, actigraphy, body position, snoring, and chest motion. As discussed, in March of this year, the Federal Motor Carrier Safety Association (FMCSA) suspended the commercial driver's required annual/biennial medical exams. This suspension was a reaction to the COVID-19 pandemic, and the nation's need to keep its commercial drivers on the road delivering essential supplies. The suspension is currently scheduled to expire on September 30, 2020. We anticipate that almost seven months of drivers will need to schedule and complete their required medical exams shortly after September 30th. Thus, whenever the suspension is lifted, it is anticipated that there will be an increased number of drivers all needing completion of their medical exams including OSA testing (when indicated).. These drivers would be in addition to our new patient accounts acquired during the past four-month period. With our implementation of this new technology, we expect to not only be more efficient in our testing process, but to greatly enable our clinic partners to process the OSA portion of their drivers' DOT medical exams faster and more efficiently. While there is an additional cost to the Company for the WatchPAT™ ONE process, we have elected to not pass this cost on to the clinic, the driver or the driver's employer. 

Item 3. Quantitative and Qualitative Disclosures about Market Risk:

As a smaller reporting company, we are not required to make any disclosure.

Item 4. Controls and Procedures

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

 

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions; (ii) provide reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; (iii) provide reasonable assurance that receipts and expenditures of company assets are made in accordance with management authorization; and (iv) provide reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because changes in conditions may occur or the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of June 30, 2020. This evaluation was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, Internal Control-Integrated Framework. Based upon such assessment, our CFO concluded that, as of June 30, 2020, our internal controls over financial reporting were not optimally effective in the specific areas described in the paragraphs below.

As of June 30, 2020, our CFO identified the following specific material weaknesses in the Company’s internal controls over its financial reporting processes:

•

Policies and Procedures for the Financial Close and Reporting Process – During the period of this report, the Company’s policies or procedures did not clearly define the roles in the financial reporting process. The various roles and responsibilities related to this process should be defined, documented, updated and communicated. Not having clear policies and procedures in place amounts to a material weakness in the Company’s internal controls over its financial reporting processes.

•

Representative with Financial Expertise – For six-month period ended June 30, 2020, the Company did not continuously have an employee with the requisite knowledge and expertise to review the financial statements and disclosures at a sufficient level to monitor the financial statements and disclosures to the Company. Failure to have, continuously, an employee with such knowledge and expertise amounts to a material weakness to the Company’s internal controls over its financial reporting processes.

As a result of our retaining the services of an Outside Accountant in January 2018 and appointing an internal Company employee to interface with the Outside Accountant, we have instituted the following policies and procedures designed to address the material weaknesses cited above.

•

All billing invoices prepared by the billing department are sent to the Outside Accountant for review and approval before sending out to the customer.

•

Copies of all incoming payable invoices are sent to the Outside Accountant for review, approval and data entry into the accounting system. That way Corporate Office has the originals and the outside accountants have duplicate copies. Accounts Payable Aging Report is sent once a week from the Outside Accountants to the Corporate office. The Corporate office, along with Outside Accountants, decide on which bills to pay weekly. Electronic payments have a duel control approval system (one person is initiating the payment and another person is approving the payment).

•

Paperwork on all customer invoices, credit card payments and check payments received at Corporate are copied and forwarded to Outside Accountants. Customer invoices are recorded daily. Customer payments received are recorded daily. Customer payments are reconciled with the bank on a daily basis. Aged Accounts Receivable Reports are sent to Corporate by the Outside Accountants with suggestions on a regular basis.

•

All bank accounts are reconciled monthly.

•

Financial Statements are prepared and reviewed monthly.

 

The Company plans to further augment its addressing of material weaknesses, on an as-needed basis, by hiring additional accounting personnel once its initial corrective steps have been fully implemented, tested and found to be effective.

PART II-OTHER INFORMATION

Item 1. Legal Proceedings

With the exception of the matter set forth below, all of the legal proceedings for the six-month period ended June 30, 2020, are disclosed in our annual report on Form 10-K filed on April 9, 2020.

Item 1A. Risk Factors

In addition to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, we include the following:

Effect of the Coronavirus Pandemic

The coronavirus pandemic is adversely affecting and is expected to continue to adversely affect our business, financial condition and results of operations. We are unable to predict the extent or nature these effects will have on our business at this time.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

With the exception of the matter set forth below, the sale of unregistered securities for the six-month period ended June 30, 2020 were disclosed in our annual report on Form 10-K filed on April 9, 2020.

On April 15, 2020, we issued a convertible promissory note (the "Note”) in the principle amount of $109,180 with an original issue discount of $6,180. The Note matures on October 15, 2021, and the interest rate is 10%. This Note may not be prepaid in whole or in part except as follows. Should the Note be prepaid within the first ninety days from the date of issuance, the prepayment percentage is one hundred and twenty-five (125%) per cent of the outstanding principal and any accrued and unpaid interest. For the next ninety days the Note may be prepaid and the prepayment percentage is one hundred thirty (130%) per cent of the outstanding principal and any accrued and unpaid interest. Thereafter, the Note may not be prepaid.

On April 21, 2020, we issued a total of 14,584,350 shares of our common stock in exchange for $2,916,869 of our Senior Debt and accrued interest to seven holders of the Debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On April 21, 2020, we issued a total of 1,327,252 shares of our common stock in exchange for $265,450 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On April 21, 2020, we issued a total of 2,156,515 shares of our common stock in exchange for $431,303 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 13, 2020, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

 

On May 15, 2020, we issued a total 1,263,745 shares of our common stock in exchange for $139,012 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 15, 2020, we issued a total 4,284,565 shares of our common stock in exchange for $471,302 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 15, 2020, we issued a total 7,210,168 shares of our common stock in exchange for $793,118 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 18, 2020, we issued a total 700,751 shares of our common stock in exchange for $77,083 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 21, 2020, we issued a total 502,434 shares of our common stock in exchange for $55,268 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 22, 2020, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On May 25, 2020, we issued a total 319,627 shares of our common stock in exchange for $35,159 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 25, 2020, we issued a total 333,824 shares of our common stock in exchange for $36,721 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 26, 2020, we issued a convertible promissory note in the principle amount of $100,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 200,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

 

On May 26, 2020, we issued a total 781,206 shares of our common stock in exchange for $85,933 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 28, 2020, we issued a total 884,555 shares of our common stock in exchange for $97,301 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 29, 2020, we issued a total 937,116 shares of our common stock in exchange for $103,083 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 1, 2020, we issued a convertible promissory note (the "Note”)in the principle amount of $56,180 with an original issue discount of $3,180. The Note matures on June 1, 2021, and the interest rate is 10%. This Note may not be prepaid in whole or in part except as follows. Should the Note be prepaid within the first ninety days from the date of issuance, the prepayment percentage is one hundred and twenty-five (125%) per cent of the outstanding principal and any accrued and unpaid interest. For the next ninety days the Note may be prepaid and the prepayment percentage is one hundred thirty (130%) per cent of the outstanding principal and any accrued and unpaid interest. Thereafter, the Note may not be prepaid.

On June 1, 2020, we issued a total 1,024,189 shares of our common stock in exchange for $112,661 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 5, 2020, we issued a total 668,797 shares of our common stock in exchange for $73,568 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 5, 2020, we issued a total 603,987 shares of our common stock in exchange for $66,438 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 12, 2020, we issued a total 1,564,245 shares of our common stock in exchange for $172,067 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 18, 2020, we issued a total 504,957 shares of our common stock in exchange for $55,545 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 21, 2020, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

 

All of the convertible promissory notes listed above were issued to accredited investors, as that term is defined under the Section 501 of Regulation D, promulgated under the Securities Act of 1933, as amended. The warrants issued in connection with the promissory notes all have a cashless exercise feature.

On March 22, 2020, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On March 31, 2020, we issued 169,551 warrants to our Chief Executive Officer in lieu of 2020 first quarter salary. The warrants have a term of five years and an exercise price of $0.39 per warrant.

On April 14, 2020, we issued 96,058 warrants to a promissory note holder, an accredited investor, in lieu of interest. The warrants have a term of five years and an exercise price of $0.19 per warrant. The warrant has a cashless feature.

On April 19, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 101,599 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 230,630 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 146,811 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 1,589,044 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 368,804 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 1,589,044 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 1,095,253 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 25, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 1, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 1, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 10, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

 

On May 11, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 19, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 3, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 6, 2020 we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 8, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 8, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 10, 2020, we issued 200,000 warrants to our consultant. The warrants have a term of three years and an exercise price of $0.35 per warrant.

On June 11, 2020 we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 14, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 20, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 22, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 24, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 24, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 27, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 30, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 30, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

We relied on Section 4 (2) of the Securities Act of 1933, as amended and or Section 501 of Regulation D promulgated under said Act as the exemption from registration under the Act.

 

Item 3. Exhibits

Documents filed as part of this Report.

Exhibit 31.1 Advanzeon Solutions, Inc. CEO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 31.2 Advanzeon Solutions, Inc. CFO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 32.1 Advanzeon Solutions, Inc. CEO Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 32.2 Advanzeon Solutions, Inc. CFO Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

		Advanzeon Solutions, Inc.
		Registrant
Date: August 19, 2020	By:	/s/ Clark A. Marcus
		Clark A. Marcus,
		Chief Executive Officer
Date: August 19, 2020	By:	/s/ Arnold B. Finestone
		Arnold B. Finestone,
		Chief Financial Officer